Nurix Therapeutics Announces Proposed Public Offering
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: GlobeNewswire
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock and, in lieu of common stock, in the case of certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions. All of the securities will be offered and sold by Nurix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, I
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study [Yahoo! Finance]Yahoo! Finance
- Biggest stock movers today: NRIX and APLD [Seeking Alpha]Seeking Alpha
- Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingGlobeNewswire
- Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Royal Bank of Canada from $22.00 to $23.00. They now have an "outperform" rating on the stock.MarketBeat
NRIX
Earnings
- 4/10/24 - Beat
NRIX
Sec Filings
- 4/12/24 - Form 8-K
- 4/12/24 - Form 424B5
- 4/11/24 - Form 424B5
- NRIX's page on the SEC website